846 Efficacy, Safety, Tolerability, and Immunological Effects of Nexvax2®, a Peptide-Based Therapeutic Vaccine, Administered by Intra-Dermal (ID) Injection Twice-Weekly for 8-Weeks in HLA-DQ2.5+ Celiac Disease (CeD)
Goel, Gautam, King, Tim, Daveson, A.J., Krishnarajah, Janakan, Brown, Gregor J., Tye-Din, Jason A., Girardin, Adam, Taavela, Juha, Popp, Alina, Maki, Markku, Goldstein, Kaela, Dzuris, John L., WilliamVolume:
150
Language:
english
Journal:
Gastroenterology
DOI:
10.1016/s0016-5085(16)30689-8
Date:
April, 2016
File:
PDF, 201 KB
english, 2016
File converter
More search results
More benefits 
